Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes.

CONCLUSIONS: These results suggest that VA-lip-siRNA HSP47 improves pulmonary fibrosis in not only preventive, but also therapeutic schedules, and thus, this drug delivery system should provide a novel therapy for refractory pulmonary fibrosis.
PMID: 29035148 [PubMed - as supplied by publisher]

Source: Experimental Lung Research - October 17, 2017 Category: Respiratory Medicine Tags: Exp Lung Res Source Type: research